Arca
Skip to content
Tools
Tools

EPHB4: Ephrin type-B receptor 4

Receptor tyrosine kinase which binds promiscuously to transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells.

  • Drugs that act on it: 3
  • Approved: 0
  • In phases 1 to 3: 3
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on EPHB4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3

Approved0

    Phase 31

    • Tesevatinib

    Phase 22

    • JI-101
    • TG100-801

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Ephrin type-B receptor 4 inhibitor.
      TesevatinibPhase 3SanofiSmall moleculeInhibitor0
      JI-101Phase 2Jubilant Innovation Ltd.Small moleculeInhibitor0
      TG100-801Phase 2TargeGenSmall moleculeInhibitor0

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Capillary malformation-arteriovenous malformation syndrome0.84
      • Lymphatic malformation 70.74
      • Medullary thyroid gland carcinoma0.54
      • Abnormality of the cardiovascular system0.53
      • Vein of Galen aneurysm0.51
      • EPHB4-associated vascular malformation spectrum0.51
      • Lymphatic malformation 10.41
      • Neoplasm0.40
      • Non-small cell lung carcinoma0.40
      • Hydrops fetalis0.38
      • Thyroid tumor0.37
      • Thyroid gland carcinoma0.37

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5147, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P54760, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.